Targets › VZGP5
1 program from 1 company in 2 trials: 2 Phase 3; Infectious disease; next expected readout Nov 2027.
Open in Phaseline: the race on VZGP5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| MAXVAX Biotechnology Limited Liability Company | Varicella Zoster Virus Envelope Glycoprotein E Envelope glycoprotein E vaccine antigen | VZGP5, VZV | Phase 3 | Herpes Zoster | Nov 2027 |
Herpes Zoster (2)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.